FDA OKs Pfizer Bavencio for maintenance of bladder cancer that has not progressed

Pfizer (NYSE:PFE) and alliance partner Merck KGaA (OTCPK:MKGAF) announce the FDA nod for Bavencio (avelumab) for the first-line maintenance treatment of locally advanced or metastatic urothelial carcinoma (UC), the most common type of bladder cancer, that has not progressed with first-line platinum-based chemo.

The agency approved the PD-L1 inhibitor in May 2017 for locally advanced or metastatic UC that has progressed during or following platinum-based chemo.

https://seekingalpha.com/news/3587624-fda-oks-pfizers-bavencio-for-maintenance-of-bladder-cancer-not-progressed